MDLN News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

MD

Mkt Cap

$28.04B

Volume

7.04M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

NASDAQ: MDLN Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the FirmKessler Topaz Meltzer & Check, LLP is investigating potential securities law violations by Medline Inc. following significant FDA violations related to manufacturing quality standards and microbial contamination. The company's stock fell over 7% after the FDA warning letter and dropped an additional 12% following disappointing Q2 results and lowered full-year guidance.GlobeNewswire Inc. · Aug 7, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Industries, Inc. - MDLNPomerantz LLP is investigating potential securities fraud claims against Medline Industries following an FDA warning letter on June 2, 2026, citing significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals. The announcement triggered a 7.16% stock price decline ($2.56 per share) to $33.19.GlobeNewswire Inc. · Jul 7, 2026

MDLN ALERT: HBSS Probes Medline (MDLN) After Reports Reveal Undisclosed Manufacturing Violations and Failed Contamination InvestigationsHagens Berman has launched an investigation into Medline Inc. (NASDAQ: MDLN) for allegedly misleading investors about manufacturing quality controls and FDA compliance. An FDA warning letter revealed systemic contamination failures and inadequate corrective actions between June 2023 and August 2025. The disclosure prompted a $2.2 billion market capitalization decline.GlobeNewswire Inc. · Jul 1, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Industries, Inc. - MDLNPomerantz LLP is investigating potential securities fraud claims against Medline Industries following an FDA warning letter on June 2, 2026, citing significant violations of Good Manufacturing Practice regulations for pharmaceuticals. The announcement triggered a 7.16% stock price decline ($2.56 per share) for Medline.GlobeNewswire Inc. · Jun 16, 2026

Medline Distribution Center Fire Creates Near-Term Headwind: AnalystMedline Inc. stock fell 2.53% on Friday following a major fire that destroyed its 1 million-square-foot distribution center in Tracy, California on Thursday. The facility represents 4% of the company's U.S. warehouse space and 3% globally. Analysts expect near-term margin pressure from inventory losses and replenishment costs, though long-term impact should be limited given Medline's scale. The stock decline was also influenced by an FDA warning letter issued last week citing significant manufacturing violations at its Waukegan facility.Benzinga · Jun 12, 2026

Medline Inc. announces pricing of upsized secondary offering of Class A common stockMedline Inc. priced a secondary offering of 72.6 million shares at $37.00 per share by major shareholders including Blackstone, Hellman & Friedman, and Abu Dhabi Investment Authority. The company reported Q1 2026 net sales of $7.4 billion (up 10.7%) but net income declined 25.8% to $239 million, with adjusted EBITDA down 10.6% to $776 million.GlobeNewswire Inc. · May 22, 2026

FDA Flags Quality System Lapses At Medline Facility Over Device RisksThe FDA issued a warning letter to Medline Inc. following an inspection of its New York facility that revealed significant quality system violations in angiographic control syringes. The inspection found manufacturing deficiencies, inadequate corrective and preventive action (CAPA) procedures despite 221 complaints, contamination risks, and insufficient design verification processes. The FDA warned of potential enforcement actions including fines or product seizures if issues are not remedied within 15 business days.Benzinga · Apr 9, 2026

Medline Inc. announces closing of secondary offering of Class A common stock and full exercise of underwriters’ option to purchase additional sharesMedline Inc. completed a secondary offering of 86.25 million shares of Class A common stock at $41.00 per share, with underwriters fully exercising their option to purchase an additional 11.25 million shares. The offering was conducted by selling stockholders affiliated with Blackstone, The Carlyle Group, Hellman & Friedman, and Abu Dhabi Investment Authority. Medline did not sell shares or receive proceeds from the offering.GlobeNewswire Inc. · Mar 10, 2026

FDA Flags Serious Safety Fire Risks In Medline Homecare BedsThe FDA classified Medline's corrective action for its Basic Homecare Beds as a Class I recall due to electrical safety risks that can cause fires and electrical shocks. The company has issued revised operating instructions rather than removing beds from sale. As of December 18, there have been 12 injuries and one death linked to overheating pendant cords, plus two additional injuries and one death from patient entrapment risks with non-Medline accessories.Benzinga · Feb 13, 2026

How the Largest IPO of 2025 Could Be Healthy for Your PortfolioMedline Industries, the largest IPO of 2025, is positioned as an attractive investment opportunity. The Chicago-based medical supply company has demonstrated strong historical growth with 18% average annual sales growth since 1966 and 50 consecutive years of net sales growth. With a $375 billion total addressable market and solid free cash flow projections, analysts expect continued momentum, though the stock trades at a lofty P/E multiple of 28.The Motley Fool · Feb 5, 2026

MD

MDLNMedline Inc. Class A common stock

MDLN

Pay with—

Available Balance0.00

Your PositionYou don't own any MDLN yet.

Related Tickers

Earnings